Strive Health's Executive Play: Fortifying Its AI and Value-Based Frontier

DENVER, CO – June 16, 2026 – Strive Health, a national leader in value-based kidney care, recently announced two key appointments to its C-suite, naming Jamie Sharp, M.D., its new chief medical officer and Chris Rigg its chief financial officer. On the surface, it’s a standard corporate press release. But beyond the headline, these hires represent a calculated and significant maneuver to solidify the company’s position at the forefront of one of healthcare’s most complex and costly challenges. The move signals a doubling down on a strategy that fuses advanced clinical models with sophisticated financial engineering and artificial intelligence, a combination Strive is betting on to dominate the future of chronic disease management.

In an industry where personnel changes are common, the specific expertise of Dr. Sharp and Mr. Rigg points directly to Strive's next phase of growth. The company is not merely filling seats; it is acquiring a specific blend of leadership designed to scale its tech-driven, risk-bearing model nationwide. As Strive's president, Paul Marchetti, noted, “Jamie and Chris stood out as the right leaders for this moment,” a statement that underscores the strategic importance of this executive reinforcement.

A Strategic Reinforcement for a High-Stakes Market

The landscape of kidney care is a high-stakes arena, burdened by staggering costs and challenging patient outcomes. Medicare spending on patients with kidney disease reached nearly $82 billion in 2018 alone, creating immense pressure on the healthcare system to find more efficient and effective models of care. This financial reality has catalyzed a systemic shift, propelled by federal programs like the Advancing American Kidney Health (AAKH) initiative, which incentivizes a move away from traditional fee-for-service payments toward value-based models that reward providers for slowing disease progression and improving quality of life.

It is within this transformative environment that Strive Health has rapidly emerged as a formidable player. Since its founding in 2018, the company has grown to serve over 150,000 patients across all 50 states, managing nearly $5 billion in annual medical spend. This growth pits it against established giants like Fresenius Medical Care and DaVita, both of which have been pivoting their massive dialysis operations toward value-based care. Strive’s edge lies in its specialized, tech-forward approach, which focuses on early identification and intervention for patients with chronic kidney disease (CKD) long before they require dialysis.

The recent executive appointments are designed to sharpen that edge. “They bring track records of success and execution that will help us strengthen our performance-based culture, keep evolving our clinical model and build on the results-oriented ways of working that continue to drive Strive’s success,” Marchetti added. This focus on a “performance-based culture” is central to succeeding in a market where financial success is directly tied to measurable clinical results.

Blending Clinical Innovation with Financial Acumen

The true significance of the hires lies in the synergy between the new executives. Dr. Jamie Sharp arrives as Chief Medical Officer with a rich background in applying technology to value-based care for complex populations. Her previous role as CMO at Rippl saw her championing tech-enabled solutions for dementia care, another challenging chronic condition. Her experience at senior levels within major healthcare organizations like Aetna, naviHealth, and Evolent Health has been consistently focused on driving better outcomes through innovative care models.

Her perspective aligns perfectly with Strive’s holistic approach. “Chronic illnesses such as kidney disease, diabetes, heart disease and hypertension affect three out of four adults and account for about 90% of healthcare spending,” Sharp stated. “Treating kidney disease is not a singular issue. Patients are often navigating multiple complex conditions that require comprehensive care and coordination.” Her mandate is to advance Strive's clinical model, which already integrates care for related conditions like congestive heart failure, ensuring the company’s medical strategy is as sophisticated as its technology.

Complementing this clinical leadership is Chris Rigg, the new Chief Financial Officer, whose background is uniquely suited to Strive's business model. More than a traditional finance chief, Rigg’s experience bridges the worlds of large-scale health insurance and Wall Street investment analysis. As the former CFO for Commercial Health Benefits at Elevance Health, he oversaw the financial strategy for a business covering over 32 million people. Before that, his work as an equity research analyst at firms like Deutsche Bank and Merrill Lynch involved advising investors specifically on managed care and value-based care trends. This history gives him an intimate understanding of what payors need and what investors value in the healthcare services sector.

“Joining Strive gives me the opportunity to bring a strategic financial perspective to the company’s partnerships and guide initiatives, ultimately driving better outcomes for patients and providers,” Rigg said. His role explicitly includes helping to “deploy AI technologies,” a rare but telling responsibility for a CFO that highlights how central technology is to Strive’s financial and operational scaling strategy.

The Engine of Growth: AI, Data, and Risk

Strive Health’s core strategy relies on its proprietary CareMultiplier™ technology platform, an AI-driven engine designed to turn vast amounts of patient data into actionable clinical intelligence. The HITRUST-certified platform uses predictive algorithms to identify at-risk patients, forecast disease progression, and guide Strive’s multidisciplinary care teams toward targeted interventions. The results have been compelling: the company reports a 20% reduction in the total cost of kidney care for its partners, a 41% reduction in hospitalizations, and over $400 million in savings, all while maintaining a 94% patient satisfaction rate. A study published in the Journal of Patient Experience further validated this model, finding that patients in Strive’s program had significantly lower hospital readmission rates.

This is where Rigg’s appointment becomes particularly critical. Scaling this model requires not only technological prowess but also substantial capital and the ability to structure complex, risk-based financial contracts with payors and health systems. Strive takes on financial risk for its patient populations, meaning it profits when it successfully keeps patients healthier and out of the hospital. This model is capital-intensive and requires sophisticated financial oversight to manage risk and ensure profitability.

The company is well-capitalized for this expansion, having secured a $550 million Series D funding round in late 2025, which pushed its valuation to $1.8 billion. This capital is earmarked for enhancing its AI tools and expanding its risk-bearing partnerships. Rigg’s expertise in both large-scale commercial health plans and value-based financial models makes him the ideal leader to architect these partnerships and ensure that Strive’s investments in technology yield a strong return for the company and its partners.

By bringing in Sharp and Rigg, Strive is building a leadership team capable of executing on both fronts of the value-based care equation: delivering superior clinical outcomes and demonstrating undeniable financial value. As CEO Chris Riopelle commented, their leadership will “accelerate Strive’s ability to deliver measurable outcomes for patients, providers and payers.” In the evolving economy of healthcare, proving that trinity of value is the ultimate key to sustainable growth and market leadership.